Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Protalex, Inc. (OTC: PRTX).

Full DD Report for PRTX

You must become a subscriber to view this report.


Recent News from (OTC: PRTX)

Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting
Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that preliminary results from its European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP) (PRTX-100-203 Study) will be pre...
Source: Business Wire
Date: May, 17 2018 09:53
Protalex initiates fourth cohort dosing of Phase 1/2 study of PRTX-100 in ITP
Protalex ( OTCQB:PRTX ) has enrolled the first of three patients in cohort four of its U.S./U.K. Phase 1/2 trial evaluating PRTX-100 for the treatment of adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-202 Study). More news on: Protalex, Inc., Healthcare stocks...
Source: SeekingAlpha
Date: April, 09 2018 08:57
Protalex Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia
Additional study sites opened in the U.K. for the 202 Study Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that the Company has enrolled the first of three patients in cohort four of its U.S./U.K. Phase 1/2 trial evaluating PRTX-100 for the t...
Source: Business Wire
Date: April, 09 2018 08:00
Protalex Announces Completion of $1.425 Million Private Placement, Recapitalization and Entry into Call Option Agreement with Its Principal Stockholder
Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that on February 28, 2018, it consummated a private placement financing to accredited investors of $1.425 million of Senior Convertible Notes. No commissions were payable in connection with the financin...
Source: Business Wire
Date: March, 01 2018 16:05
Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune Thrombocytopenia
U.S. 202 ITP Study to Expand Enrollment with Opening of Sites in U.K. Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the fourth dose cohort of its European Phase 1b study of PRTX-100 (PRT...
Source: Business Wire
Date: January, 18 2018 08:00
Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP
Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the third dose cohort of its European Phase 1b study of PRTX-100, the Company’s highly purified form of Staphylococcal protein A (SpA,) in ad...
Source: Business Wire
Date: November, 13 2017 09:00
NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on October 26, 2017
Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CMLS 115.33% – News: Post preliminary Q3 2017 operating results MYOS 32.21% – News: Partners with Pro Football Legends in support of...
Source: NetworkNewsWire
Date: October, 26 2017 12:00
Protalex Announces Publication in the British Journal of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia
Protalex, Inc. (OTCQB:PRTX) , a clinical-stage biopharmaceutical company, announces that preclinical data showing its lead drug candidate PRTX-100 increases blood platelet counts in a murine model of immune thrombocytopenia (ITP) were published in the recent issue of the peer-reviewed journ...
Source: Business Wire
Date: October, 26 2017 08:00
FDA awards 15 grants to support product development for rare diseases
The FDA is doing its part to advance products to treat rare diseases with 15 new clinical trial research grants totaling more than $22M over the next four years. The funding is being provided through the Orphan Products Clinical Trials Grants Program. More news on: Tocagen Inc, Protalex,...
Source: SeekingAlpha
Date: October, 06 2017 11:50
Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP
New Trial Sites in the U.K. Open and Enrolling Patients Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the second dose cohort of its European Phase 1b study of PRTX-100 in adults with per...
Source: Business Wire
Date: August, 29 2017 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-200.230.230.230.231,043
2018-08-170.250.230.250.2258,088
2018-08-150.300.250.350.1513,381
2018-08-140.3250.350.350.3251,990
2018-08-130.35010.330.3820.2581,156

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-171008,0881.2364Cover
2018-08-1530013,3812.2420Cover
2018-08-1333,56181,15641.3537Short
2018-08-081,0005,86217.0590Cover
2018-08-021003,7802.6455Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PRTX.


About Protalex, Inc. (OTC: PRTX)

Logo for Protalex, Inc. (OTC: PRTX)

Protalex is a clinical stage biopharmaceutical company focused on the development of a class of drugs for treating rare and autoimmune and inflammatory diseases including rheumatoid arthritis and Immune Thrombocytopenia.

 

Contact Information

 

 

Current Management

  • Arnold P. Kling / President
  • Kirk M. Warshaw / CFO
  • Marco M. Elser /
  • Arnold P. Kling /
  • Kirk M. Warshaw /

 


Recent Filings from (OTC: PRTX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 13 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: March, 09 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: January, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: October, 11 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: September, 13 2017
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: August, 23 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 05 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: January, 12 2017

 

 


Daily Technical Chart for (OTC: PRTX)

Daily Technical Chart for (OTC: PRTX)


Stay tuned for daily updates and more on (OTC: PRTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PRTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PRTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of PRTX and does not buy, sell, or trade any shares of PRTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/